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7L with shRNA, or overexpressed either wt APOBEC3B, or a 
catalytically dead mutant APOBEC3B. 
 
Results: Radioresistant breast cancer cells had increased 
baseline APOBEC3B mRNA levels (and not of any of the other 
APOBEC proteins), and irradiation induced an increase in 
APOBEC3B expression in both MCF7 and MDA-MB231 cells. In 
the breast cancer patient cohort we found a strong, 
statistically significant, independent interaction between 
APOBEC3B expression and radiotherapy. APOBEC3B predicted 
a poor prognosis only in those patients that received 
radiotherapy as part of their primary treatment, also when 
this analysis was restricted to patients that received a 
mastectomy (figure). This suggests that APOBEC3B influences 
radiosensitivity, and does not merely predict efficacy of 
surgery (as radiotherapy is generally given to lumpectomy 
patients). The effect of APOBEC3B knockdown and 
overexpression on radiosensitivity is currently being assessed 
using colony-forming assays and will be presented. 
 
 
Conclusion: Our data suggest that the anti-viral APOBEC3B 
enzyme influences radiosensitivity in breast cancer, and 
might be a potential target for radiosensitization. 
 
Proffered Papers: Clinical 9: SBRT and oligometastatic 
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Purpose or Objective: To determine the radiographic 
response of Hepatocellular Carcinoma (HCC) lesions treated 
via stereotactic body radiotherapy (SBRT) in a series of liver 
transplant candidates and to correlate these findings with 
pathology after transplant. 
 
Material and Methods: We retrospectively reviewed 17 liver 
transplant candidates from December 2008 to December 2013 
at a single institution with discrete HCC lesions were treated 
with SBRT for evaluation of local control (LC); other methods 
of bridging patients to transplant were also available. 
Peripheral SBRT dose was either 50 Gy in 5 fractions or 45 Gy 
in 3 fractions with 2 fractions weekly. The records of 
transplant patients who underwent SBRT for single or 
multiple hepatomas were reviewed for maximum tumor 
dimension (MTD) at time of simulation, last imaging before 
transplant, and gross pathology following transplant. 
Radiographic LC of the treated lesion was defined as stable 
or decreasing enhancement on imaging with either triple-
phase CT Liver or MRI Liver prior to transplant as 
demonstrated in Figure 1; this was recorded one month 
subsequent to treatment and just before the transplant. 
Pathologic Control (PC) was defined as stable to decreased 
size in MTD and/or no viable tumor present. 
 
 
 
Results: Twelve patients have successfully been 
transplanted. All patients were male with a median age of 57 
years. Of the 12 patients transplanted, there were 17 lesions 
treated. Median MTD at time of radiation was 3.6 cm (1.1cm 
- 6.1 cm). Median time to transplant from radiation 
treatment for 12 patients was 9 months (2mo-18mo). Table 1 
summarizes tumor and treatment characteristics. Eight 
lesions (47%) had no evidence of viable tumor on pathology. 
Radiographic LC and PC was achieved in all 17 lesions. At a 
median follow-up of 53 months, disease free and overall 
survival were 100% with no evidence of disease (NED). Of the 
remaining 5 candidates, 3 patients awaiting transplant had 
one lesion, 1 had two lesions, and 1 had three lesions treated 
via SBRT. No patient experienced significant decrement in 
liver function nor indication of radiation induced liver 
disease. One patient experienced Grade 1 abdominal pain 
and three patients experienced Grade 1 nausea. 
 
 
 
Conclusion: SBRT for HCC lesions in transplant candidates is 
an effective means of LC with successful bridging to 
transplant. Radiologic assessment subsequent to SBRT 
correlated with pathologic findings after transplant. These 
promising results suggest a broader role for SBRT in 
management of limited volume HCC. 
 
 
 
 
 
